Back to drug list

Aldurazyme (laronidase)


Billing

Code: J1931

Description: Laronidase injection

Unit: 0.1 mg

Payment: $37.438

Pay quarter: Q4 2023


Medicare history

Dosage and Frequency

Mucopolysaccharidosis I (MPS I)

• 0.58mg/kg IV every 1 week

Calculate drug reimbursement


Total Reimbursement:

$17,371.23

(ASP: $16,387.95, Margin: $983.28)


Code:

J1931

# Units to bill:

464

Prior Authorization

Prior auth criteria for Aldurazyme may include but is not limited to:


1. The patient must have been diagnosed with mucopolysaccharidosis type I (MPS I), a rare genetic disorder caused by a deficiency in the enzyme alpha-L-Iduronidase (IDUA).

2. The patient must have a confirmed diagnosis of MPS I based on clinical signs and symptoms, and laboratory tests.

3. The patient must be aged 2 years or older.

4. The patient must have failed to respond to an adequate trial of an alternative therapy, or have an intolerance to the alternative therapy.

5. The patient must be able to receive and metabolize Aldurazyme.

6. The patient must have documentation of informed consent prior to initiation of therapy.


Insurance prior auth guidelines:

Aetna

United Healthcare

Anthem

Cigna


Billable NDCs

58468-0070-01

Aldurazyme (GENZYME CORPORATION)

2.9000000000000004 MG



Resources

Website